Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

NCT01616303 is registered in ClinicalTrials.gov with Quest PharmaTech Inc. as lead sponsor.

NCT NCT01616303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01616303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma
Lead sponsor
Quest PharmaTech Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2012
Completion date
October 12, 2018
Enrollment
97 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms